In-Depth Profiling of T-Cell Responsiveness to Commonly Recognized CMV Antigens in Older People Reveals Important Sex Differences.
Cytomegalovirus (CMV)
T cell
aging
biological sex
immunosenescence
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
05
2021
accepted:
26
07
2021
entrez:
6
9
2021
pubmed:
7
9
2021
medline:
15
12
2021
Statut:
epublish
Résumé
The impact of biological sex on T-cell immunity to Cytomegalovirus (CMV) has not been investigated in detail with only one published study comparing CMV-specific T-cell responses in men and women. Many studies, however, have shown an association between CMV infection and immunosenescence, with broad effects on peripheral blood lymphocyte subsets as well as the T and B-cell repertoires. Here, we provide a detailed analysis of CMV-specific T-cell responses in (n=94) CMV+ older people, including 47 women and 47 men aged between 60 and 93 years. We explore sex differences with respect to 16 different CMV proteins arranged in 14 peptide pools (overlapping peptides). Following ex vivo stimulation, CD4 and CD8 T-cells producing IFN-γ, TNF, and IL-2 were enumerated by flow-cytometry (intracellular cytokine staining). T-cell responses were evaluated in terms of each cytokine separately or in terms of cytokines produced simultaneously (polyfunctionality). Surface memory phenotype and CD3 downmodulation were assessed in parallel. The polyfunctionality index and a memory subset differentiation score were used to identify associations between response size, cytokine production, polyfunctionality, and memory subset distribution. While no significant sex differences were found with respect to overall CMV target protein selection, the T-cell response in men appeared more focused and accompanied by a more prominent accumulation of CMV-specific memory CD4 and CD8 T-cells. T-cell polyfunctionality and differentiation were similar in the sexes, however, CMV-specific T-cells in men produced more pro-inflammatory cytokines. Particularly, TNF production by CD4 T-cells was stronger in men than in women. Also, compared with women, men had larger responses to CMV proteins with immediate-early/early kinetics than women, which might have been driven by CMV reactivation. In conclusion, the CMV-specific T-cell response in men was larger and more pro-inflammatory than in women. Our findings may help explain sex differences in CMV-associated pathologies.
Identifiants
pubmed: 34484207
doi: 10.3389/fimmu.2021.707830
pmc: PMC8414256
doi:
Substances chimiques
Antigens, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
707830Informations de copyright
Copyright © 2021 Reus, Caserta, Larsen, Morrow, Bano, Hallensleben, Rajkumar, Pera and Kern.
Déclaration de conflit d'intérêts
FK is employed part-time by JPT Peptide Technologies (Germany). ML is the proprietary owner of Funky Cells software. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Immunity. 2008 Oct 17;29(4):520-2
pubmed: 18957264
Eur J Immunol. 1997 Sep;27(9):2195-203
pubmed: 9341759
BMJ Glob Health. 2017 Mar 27;2(2):e000298
pubmed: 28589033
Rev Med Virol. 2010 Jul;20(4):202-13
pubmed: 20564615
J Virol. 2007 Jul;81(14):7759-65
pubmed: 17409149
J Immunol. 2013 Mar 15;190(6):2767-77
pubmed: 23390296
Med Microbiol Immunol. 2019 Aug;208(3-4):365-373
pubmed: 30989333
Exp Gerontol. 2014 Jun;54:130-7
pubmed: 24440462
J Immunol. 2009 Feb 1;182(3):1548-59
pubmed: 19155503
Cytometry A. 2010 Sep;77(9):873-80
pubmed: 20629196
J Virol. 2002 Nov;76(21):10929-41
pubmed: 12368336
J Virol. 1982 Feb;41(2):462-77
pubmed: 6281461
Immun Ageing. 2012 Oct 31;9(1):23
pubmed: 23114110
Nat Immunol. 2016 Apr;17(4):379-86
pubmed: 26901151
PLoS One. 2012;7(7):e42403
pubmed: 22860124
Eur J Immunol. 2000 Jun;30(6):1676-82
pubmed: 10898504
Stroke. 2013 Dec;44(12):3318-23
pubmed: 24130138
Front Immunol. 2021 Apr 22;12:668885
pubmed: 33968074
Exp Gerontol. 2019 Jul 1;121:46-54
pubmed: 30885717
J Rheumatol. 1999 Jul;26(7):1452-7
pubmed: 10405929
J Exp Med. 1996 Apr 1;183(4):1917-21
pubmed: 8666949
Sci Rep. 2016 May 31;6:26892
pubmed: 27243552
Mech Ageing Dev. 2016 Sep;158:14-22
pubmed: 26957355
Ann N Y Acad Sci. 2006 May;1067:56-65
pubmed: 16803971
PLoS One. 2015 Jun 05;10(6):e0128714
pubmed: 26046523
J Exp Med. 2005 Sep 5;202(5):673-85
pubmed: 16147978
J Infect Dis. 2017 Apr 15;215(8):1212-1220
pubmed: 28199648
J Virol. 2012 Jan;86(2):1001-9
pubmed: 22072753
J Virol. 1999 Jul;73(7):5757-66
pubmed: 10364327
Immun Ageing. 2016 Jan 05;13:1
pubmed: 26734066
Theranostics. 2018 Aug 07;8(16):4509-4519
pubmed: 30214635
J Interferon Cytokine Res. 2006 Dec;26(12):887-92
pubmed: 17238831
Nat Med. 2007 Jul;13(7):843-50
pubmed: 17558415
J Biosci Med. 2011 Jan;1(1):
pubmed: 22318485
Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):E10586-E10595
pubmed: 29158406
mBio. 2018 Mar 13;9(2):
pubmed: 29535194
J Gen Virol. 2020 Jun;101(6):635-644
pubmed: 32375946
Sci Rep. 2016 Apr 19;6:24674
pubmed: 27091512
Hum Immunol. 2004 May;65(5):476-85
pubmed: 15172447
J Exp Med. 2007 Jun 11;204(6):1405-16
pubmed: 17535971
J Biol Chem. 1998 Apr 3;273(14):8119-29
pubmed: 9525915
Science. 1996 Jul 5;273(5271):104-6
pubmed: 8658175
J Infect Dis. 2016 Nov 1;214(9):1430-1437
pubmed: 27521364
Theranostics. 2021 Mar 31;11(12):5728-5741
pubmed: 33897878
PLoS Pathog. 2013;9(10):e1003635
pubmed: 24130479
Int J Biochem Cell Biol. 2009 Mar;41(3):503-6
pubmed: 18992841
J Immunol Methods. 2001 Sep 1;255(1-2):27-40
pubmed: 11470284
Biogerontology. 2015 Oct;16(5):631-43
pubmed: 25732234